bluebird slips after latest LentiGlobin update

bluebird bio Inc. (NASDAQ:BLUE) lost $5.10 (11%) to $41.30 after reporting new results from three Phase I/II studies of LentiGlobin BB305 gene therapy, which the company is developing to treat sickle cell disease (SCD) and beta-thalassemia. The announcement came ahead of the company's planned presentations next

Read the full 462 word article

User Sign In